Literature DB >> 15467427

Expression analysis of the epigenetic methyltransferases and methyl-CpG binding protein families in the normal B-cell and B-cell chronic lymphocytic leukemia (CLL).

Harikrishnan Kn1, Sahar Bassal, Chris Tikellis, Assam El-Osta.   

Abstract

The importance of epigenetic modifications in carcinogenesis has been a source of controversy for some time. There is little doubt that changes in genomic hypermethylation contribute to the silencing of tumor suppressor genes. Furthermore, recent studies have also identified the significance of genomic hypomethylation associated with chromosomal instability and tumorigenesis. One of the most perplexing questions regarding epigenetic modifications and leukemogenesis is the relationship with DNA methyltransferases (DNMT's). The primary function of the DNMT enzymes is to methylate genomic DNA, whereas the methyl-CpG binding domain proteins (MBD) interpret this methylation signal and regulate gene expression and chromatin behavior. In this study we analyse these gene families by quantitative real-time PCR to investigate whether expression levels and the B-cell chronic lymphocytic leukemia (B-CLL) phenotype are associated. Furthermore, given the epigenetic crosstalk between genome stability and the histone chromatin code we have analysed eukaryotic histone methyltransferase (Eu-HMTaseI). Surprisingly, we did not observe significant changes in DNMT1 expression in B-CLL cases when compared to normal lymphocytes, regardless of whether we normalise against GAPDH or PCNA as reference standards. Indeed, expression of the maintenance and de novo methylases were independently regulated. Of particular note was the significant down regulation of DNMT3b. Furthermore, we observed a positive correlation between HMTaseI expression levels and stage of leukemia suggesting that changes in the methylation patterns in B-CLL may represent deregulation of the epigenetic repertoire that also include the methylation dependent binding proteins, MBD2 and MeCP2. We envisage changes in the epigenetic program are multifactorial in nature and postulate that the prevalent genomic methylases just one component of a larger epigenetic repertoire.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15467427     DOI: 10.4161/cbt.3.10.1137

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  10 in total

1.  Multiple modes of interaction between the methylated DNA binding protein MeCP2 and chromatin.

Authors:  Tatiana Nikitina; Xi Shi; Rajarshi P Ghosh; Rachel A Horowitz-Scherer; Jeffrey C Hansen; Christopher L Woodcock
Journal:  Mol Cell Biol       Date:  2006-11-13       Impact factor: 4.272

2.  Epigenetic regulation of WNT signaling in chronic lymphocytic leukemia.

Authors:  Lynda B Bennett; Kristen H Taylor; Gerald L Arthur; Farahnaz B Rahmatpanah; Sam I Hooshmand; Charles W Caldwell
Journal:  Epigenomics       Date:  2010-02-01       Impact factor: 4.778

Review 3.  Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis.

Authors:  Mohammad Shahjahani; Javad Mohammadiasl; Fatemeh Noroozi; Mohammad Seghatoleslami; Saeid Shahrabi; Fakhredin Saba; Najmaldin Saki
Journal:  Cell Oncol (Dordr)       Date:  2015-01-07       Impact factor: 6.730

Review 4.  Uncovering the DNA methylome in chronic lymphocytic leukemia.

Authors:  Nicola Cahill; Richard Rosenquist
Journal:  Epigenetics       Date:  2013-01-15       Impact factor: 4.528

Review 5.  Epigenetic roots of immunologic disease and new methods for examining chromatin regulatory pathways.

Authors:  Ian A MacDonald; Nathaniel A Hathaway
Journal:  Immunol Cell Biol       Date:  2014-12-23       Impact factor: 5.126

6.  Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia.

Authors:  Sonia Fabris; Valentina Bollati; Luca Agnelli; Fortunato Morabito; Valeria Motta; Giovanna Cutrona; Serena Matis; Anna Grazia Recchia; Vincenzo Gigliotti; Massimo Gentile; Giorgio Lambertenghi Deliliers; Pier Alberto Bertazzi; Manlio Ferrarini; Antonino Neri; Andrea Baccarelli
Journal:  Epigenetics       Date:  2011-02-01       Impact factor: 4.528

7.  Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL.

Authors:  Shilu Amin; Meagan Walsh; Caroline Wilson; Anton E Parker; David Oscier; Elaine Willmore; Derek Mann; Jelena Mann
Journal:  J Cell Mol Med       Date:  2012-09       Impact factor: 5.310

8.  Combining cytogenetic and epigenetic approaches in chronic lymphocytic leukemia improves prognosis prediction for patients with isolated 13q deletion.

Authors:  Cristina Bagacean; Christelle Le Dantec; Christian Berthou; Adrian Tempescul; Hussam Saad; Anne Bordron; Mihnea Zdrenghea; Victor Cristea; Nathalie Douet-Guilbert; Yves Renaudineau
Journal:  Clin Epigenetics       Date:  2017-11-28       Impact factor: 6.551

9.  Alterations in DNA methylation/demethylation intermediates predict clinical outcome in chronic lymphocytic leukemia.

Authors:  Cristina Bagacean; Adrian Tempescul; Christelle Le Dantec; Anne Bordron; Audrey Mohr; Hussam Saad; Valerie Olivier; Mihnea Zdrenghea; Victor Cristea; Pierre-François Cartron; Nathalie Douet-Guilbert; Christian Berthou; Yves Renaudineau
Journal:  Oncotarget       Date:  2017-08-09

Review 10.  Proteins that bind methylated DNA and human cancer: reading the wrong words.

Authors:  L Lopez-Serra; M Esteller
Journal:  Br J Cancer       Date:  2008-05-27       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.